• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Availability and payer coverage of BRCA1/2 tests and gene panels.

作者信息

Clain Elizabeth, Trosman Julia R, Douglas Michael P, Weldon Christine B, Phillips Kathryn A

机构信息

Albert Einstein College of Medicine, Bronx, New York, USA.

Center for Business Models in Healthcare, Chicago, Illinois, USA.

出版信息

Nat Biotechnol. 2015 Sep;33(9):900-2. doi: 10.1038/nbt.3322.

DOI:10.1038/nbt.3322
PMID:26348951
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4625918/
Abstract
摘要

相似文献

1
Availability and payer coverage of BRCA1/2 tests and gene panels.BRCA1/2检测及基因组合的可及性与支付方覆盖情况。
Nat Biotechnol. 2015 Sep;33(9):900-2. doi: 10.1038/nbt.3322.
2
2019 SEOM guidelines (the end of a decade).2019年西班牙肿瘤医学学会指南（十年之终）
Clin Transl Oncol. 2020 Feb;22(2):169-170. doi: 10.1007/s12094-020-02309-7. Epub 2020 Feb 6.
3
Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.医疗保险对遗传性癌症检测套餐的覆盖情况：障碍、机遇及对精准医疗计划的影响
J Natl Compr Canc Netw. 2017 Feb;15(2):219-228. doi: 10.6004/jnccn.2017.0022. Epub 2017 Feb 10.
4
Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.多基因检测面板检测出的致病性BRCA1/2突变率相同，与仅对有遗传性乳腺癌风险的患者进行有限的BRCA1/2分析相比，具有更高的诊断率。
Ann Surg Oncol. 2015 Oct;22(10):3282-8. doi: 10.1245/s10434-015-4754-2. Epub 2015 Jul 29.
5
Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.特拉华州家族性胰腺癌的全州回顾性研究以及胰腺癌家族中基因突变的频率。
Ann Surg Oncol. 2016 May;23(5):1729-35. doi: 10.1245/s10434-015-5026-x. Epub 2016 Jan 4.
6
Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening.靶向新一代测序与桑格测序用于BRCA1和BRCA2突变筛查的比较
Ann Lab Med. 2016 Mar;36(2):197-201. doi: 10.3343/alm.2016.36.2.197.
7
Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.多基因panel 检测在遗传性乳腺癌和卵巢癌风险评估中的临床可操作性。
JAMA Oncol. 2015 Oct;1(7):943-51. doi: 10.1001/jamaoncol.2015.2690.
8
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.BRCA1 和 BRCA2 基因突变携带者乳腺癌术后卵巢切除术对生存的影响。
JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.
9
AGO Austria recommendations for genetic testing of patients with ovarian cancer.奥地利AGO关于卵巢癌患者基因检测的建议。
Wien Klin Wochenschr. 2015 Aug;127(15-16):652-4. doi: 10.1007/s00508-015-0814-7.
10
Population Frequency of Germline BRCA1/2 Mutations.种系BRCA1/2突变的人群频率
J Clin Oncol. 2016 Dec;34(34):4183-4185. doi: 10.1200/JCO.2016.67.0554. Epub 2016 Oct 31.

引用本文的文献

1
Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.私人支付方和医疗保险对循环肿瘤 DNA 检测在癌症诊断和治疗中的使用的覆盖政策。
J Natl Compr Canc Netw. 2023 Jun;21(6):609-616.e4. doi: 10.6004/jnccn.2023.7011.
2
Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018.2013 - 2018年阿肯色州遗传性癌症风险基因检测的全州趋势及相关因素
Hered Cancer Clin Pract. 2022 May 23;20(1):19. doi: 10.1186/s13053-022-00226-0.
3
Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.先前无信息的癌症遗传学评估患者的重复检测结果。
Fam Cancer. 2022 Jul;21(3):375-385. doi: 10.1007/s10689-021-00276-8. Epub 2021 Sep 21.
4
A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries.新兴国家转移性去势抵抗性前列腺癌中实施精准肿瘤学的叙述性综述
Oncol Ther. 2021 Dec;9(2):311-327. doi: 10.1007/s40487-021-00160-6. Epub 2021 Jul 8.
5
Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.在瑞士和韩国遗传性乳腺癌和卵巢癌家庭中使用定制数字健康干预进行家庭沟通和级联基因检测：DIALOGUE研究方案
JMIR Res Protoc. 2021 Jun 11;10(6):e26264. doi: 10.2196/26264.
6
Interventions Facilitating Family Communication of Genetic Testing Results and Cascade Screening in Hereditary Breast/Ovarian Cancer or Lynch Syndrome: A Systematic Review and Meta-Analysis.促进遗传性乳腺癌/卵巢癌或林奇综合征基因检测结果的家庭沟通及级联筛查的干预措施：一项系统评价和荟萃分析
Cancers (Basel). 2021 Feb 23;13(4):925. doi: 10.3390/cancers13040925.
7
The role of genomics in global cancer prevention.基因组学在全球癌症预防中的作用。
Nat Rev Clin Oncol. 2021 Feb;18(2):116-128. doi: 10.1038/s41571-020-0428-5. Epub 2020 Sep 24.
8
Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.从 2015 年到 2019 年美国私人支付者对肿瘤测序覆盖范围增加的时间评估中得到的见解。
Value Health. 2020 May;23(5):551-558. doi: 10.1016/j.jval.2020.01.018. Epub 2020 Mar 19.
9
The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace.全球下一代测序检测市场持续迅猛发展。
J Precis Med. 2018 Oct;4.
10
From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.从过去到现在：下一代肿瘤测序的保险覆盖框架。
Value Health. 2018 Sep;21(9):1062-1068. doi: 10.1016/j.jval.2018.06.011. Epub 2018 Aug 3.

本文引用的文献

1
Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers.基因检测保险覆盖趋势：对美国最大支付方公开政策的综述
Per Med. 2013 May;10(3):235-243. doi: 10.2217/pme.13.9.
2
Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.下一代肿瘤测序 panel 覆盖政策制定面临的挑战：专家和支付方发表意见。
J Natl Compr Canc Netw. 2015 Mar;13(3):311-8. doi: 10.6004/jnccn.2015.0043.
3
Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment.用于遗传性乳腺癌和妇科癌症风险评估的下一代测序技术
Curr Opin Obstet Gynecol. 2015 Feb;27(1):23-33. doi: 10.1097/GCO.0000000000000141.
4
Development of the clinical next-generation sequencing industry in a shifting policy climate.临床新一代测序行业在不断变化的政策环境中的发展。
Nat Biotechnol. 2014 Oct;32(10):980-2. doi: 10.1038/nbt.3030.
5
Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.临床评估多基因测序 panel 用于遗传性癌症风险评估。
J Clin Oncol. 2014 Jul 1;32(19):2001-9. doi: 10.1200/JCO.2013.53.6607. Epub 2014 Apr 14.
6
Two decades after BRCA: setting paradigms in personalized cancer care and prevention.BRCA 研究二十年：开创个体化癌症治疗与预防的新纪元。
Science. 2014 Mar 28;343(6178):1466-70. doi: 10.1126/science.1251827.
7
Cancer risk assessment using genetic panel testing: considerations for clinical application.使用基因检测板进行癌症风险评估：临床应用的考量
J Genet Couns. 2014 Aug;23(4):604-17. doi: 10.1007/s10897-014-9695-6. Epub 2014 Mar 7.
8
Myriad decision aftershocks ripple through biotech.无数决策余波在生物技术领域泛起涟漪。
Nat Biotechnol. 2013 Aug;31(8):663-5. doi: 10.1038/nbt0813-663.
9
Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?癌症易感性的多重基因检测：在没有安全网的高空绳索上行走？
J Clin Oncol. 2013 Apr 1;31(10):1267-70. doi: 10.1200/JCO.2012.46.9403. Epub 2013 Mar 4.
10
Barriers to the use of personalized medicine in breast cancer.乳腺癌个体化医学应用的障碍。
J Oncol Pract. 2012 Jul;8(4):e24-31. doi: 10.1200/JOP.2011.000448. Epub 2012 May 22.